Clal Biotechnology Industries

IT: CBI

NIS274.3m market cap

NIS1.7 last close

Clal Biotechnology Industries is a healthcare investment company focused on investing in a variety of therapeutic, diagnostic, and medical device companies covering a full range of development phases from preclinical to post-market.

Investment summary

Clal Biotechnology Industries (CBI) recently published its Q219 update. Notably, MediWound (35% owned by CBI) announced that following a meeting to discuss the submission of a biologics licensing application (BLA) with the FDA, it expects to file for approval for NexoBrid in Q220. The submission needs to wait for the 12-month follow-up results from the Phase III DETECT study (acute data were released in January). MediWound expects to initiate a 174-patient Phase II study of EscharEx to treat venous leg ulcers in Q419 with an interim look by the end of 2020 and completion of the trial by the end of 2021.

Y/E Dec
Revenue (NISm)
EBITDA (NISm)
PBT (NISm)
EPS (NIS)
P/E (x)
P/CF (x)
2017A 73.6 (103.3) (54.2) (15.02) N/A N/A
2018A 85.3 (54.0) (40.9) (18.21) N/A N/A
2019E N/A N/A N/A N/A N/A N/A
2020E N/A N/A N/A N/A N/A N/A
Last updated on 13/09/2019
Industry outlook

CBI is invested in a variety of life science companies, including a wide and diverse range of technologies, indications and stages of development, all of which have high potential.

Last updated on 13/09/2019
Sector
Healthcare
Share price graph
Balance sheet
Forecast net debt (NISm) N/A
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 12.0 (27.1) (49.9)
Relative* 11.4 (30.5) (51.5)
52-week high/low NIS3.7/NIS1.5
*% relative to local index
Key management
Ofer Gonen CEO
Assaf Segal CFO
Gilad Rosenberg Medical Director
Ofer Goldberg Vice President